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Introduction: Feline allergic asthma is a common lower airway disease that has a complex underlying
immunopathogenesis.  Current therapeutic mainstays (glucocorticoids, bronchodilators) do not address the
underlying immune regulatory dysfunction.  Several new immunomodulators have been recently
investigated in experimental models and clinical studies of allergic disease.  The aim of this thesis was to
review the immunomodulators that have been previously evaluated in feline asthma and to specifically
evaluate the immunomodulator, feG-COOH (feG), in an experimental model of feline asthma.
	Our laboratory previously evaluated the effect of a single dose of feG on eosinophilic airway inflammation
when given prior to an allergen challenge in experimentally asthmatic cats.  While this single dose partially
blunted airway inflammation compared with placebo, this therapy needed to be tested with more chronic
use, given that exposure to allergen in pet cats is an unpredictable event.  We hypothesized that a chronic
(2 week) course of feG in experimentally asthmatic cats would decrease airway inflammation and clinical
signs of asthma. 

Methods:  Experimental asthma was induced in 10 cats using Bermuda grass allergen (BGA) and cats were
randomly selected to receive either feG (1 mg/kg, PO) or saline for 2 weeks, followed by a 2 week washout
period.  Cats then received the alternate treatment.  Cytologic examination of bronchoalveolar lavage fluid
(BALF) was used to document the development of an asthmatic phenotype prior to enrollment into the
study (this disqualified one cat from the study).  Aerosol challenge with BGA was performed weekly
throughout the study.  A clinical scoring system to evaluate clinical signs associated with the asthmatic
phenotype, was employed prior to and after each 2 week treatment.  Similarly, BALF and blood were
collected prior to and after each of the 2 week treatment periods.  Cytology and cytokine analysis were
performed on BALF samples and in vitro cytokine restimulation was performed on peripheral blood
mononuclear cells (PBMCs).

Results:  There was no significant difference between the treatment groups in BALF total nucleated cell
counts or eosinophil percentages.  Greater than 40% of the BALF supernatant samples had IL-1, IL-4, IL-6,
CXCL-8 (formerly IL-8) and IFN-Î³ concentrations below the lower limit of detection of the assay regardless
of time point or treatment administered.  Interleukin-4 and IFN-Î³ concentrations in the cell culture
supernatant from stimulated PBMCs were below the lower limit of detection for all samples.  Due to the low
number of samples that had detectable concentrations of IL-1, IL-4, IL-6, CXCL-8 and IFN-Î³, statistical
analyses of this data was not meaningful.  There was no significant difference in BALF or plasma TNF
activity or clinical scores between treatment groups.

Conclusions:  In cats with experimental asthma, daily use of feG (2 weeks) during chronic aeroallergen
exposure did not dampen eosinophilic airway inflammation, alter cytokine profiles in the plasma or BALF, or
decrease clinical signs associated with allergen challenge.  These results support that feG at this dosage
can not be recommended as monotherapy for the chronic treatment of allergic asthma in cats.  Whether
feG has a role in the acute management of asthmatic attacks or in combination with other treatments in
cats has yet to be determined.
